中文

恒瑞医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-23
ItemAmountY/Y
Revenue¥8.14B+13.0%
Gross profit¥7.05B
Operating income¥2.61B
Net income¥2.28B+21.6%
Gross margin86.6%Net margin 28.0%
Revenue Q/Q-3.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥1.09B13.4%
R&D¥1.65B20.3%
SG&A¥2.81B34.6%
Tax & other¥0.33B4.0%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

万华化学恒力石化江西铜业中航机载国电南瑞小商品城华鲁恒升片仔癀通威股份士兰微中国动力中金黄金

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies